SHAREHOLDER NOTICE: Brodsky & Smith Announces an Investigation of Arcadia Biosciences, Inc. (Nasdaq – RKDA)

BALA CYNWYD – December 5, 2024 /Globe Newswire/ – Law office of Brodsky & Smith announces that it is investigating potential claims against the Board of Directors of Arcadia Biosciences, Inc. (“Arcadia” or the “Company”) (Nasdaq – RKDA) for possible breaches of fiduciary duty and other violations of federal and state law in connection with the merger of the Company to Roosevelt Resources LP. Under the terms of the agreement, following the closing of the transaction, the current equity owners of Roosevelt and the Arcadia shareholders as of the closing are expected to own approximately 90% and 10%, respectively.

The investigation concerns whether the Arcadia Board breached its fiduciary duties to shareholders by failing to conduct a fair process, including the dilution of the Company’s shareholders in the combined company.

If you own shares of Arcadia stock and wish to discuss the legal ramifications of the investigation, or have any questions, you may e-mail or call the law office of Brodsky & Smith who will, without obligation or cost to you, attempt to answer your questions. You may contact Jason L. Brodsky, Esquire, or Marc L. Ackerman by email at clients@brodsky-smith.com, or call toll free 855-576-4847.

Brodsky & Smith is a litigation law firm with extensive expertise representing shareholders throughout the nation in securities and class action lawsuits. The attorneys at Brodsky & Smith have been appointed by numerous courts throughout the country to serve as lead counsel in class actions and have successfully recovered millions of dollars for our clients and shareholders. Attorney advertising. Prior results do not guarantee a similar outcome.